Hazlett, Burt & Watson’s NovoCure NVCR Stock Holding History

Hazlett, Burt & Watson’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1K	Hold	65	–	–	﹤0.01%	891
2025 Q4	$1K	Hold	65	–	–	﹤0.01%	900
2025 Q3	$1K	Hold	65	–	–	﹤0.01%	856
2025 Q2	$1K	Hold	65	–	–	﹤0.01%	774
2025 Q1	$1K	Hold	65	–	–	﹤0.01%	766
2024 Q4	$2K	Hold	65	–	–	﹤0.01%	709
2024 Q3	$1K	Hold	65	–	–	﹤0.01%	707
2024 Q2	$1K	Hold	65	–	–	﹤0.01%	687
2024 Q1	$1K	Hold	65	–	–	﹤0.01%	686
2023 Q4	$1K	Hold	65	–	–	﹤0.01%	661
2023 Q3	$1K	Hold	65	–	–	﹤0.01%	688
2023 Q2	$3K	Hold	65	–	–	﹤0.01%	599
2023 Q1	$4K	Hold	65	–	–	﹤0.01%	539
2022 Q4	$5K	Hold	65	–	–	﹤0.01%	522
2022 Q3	$5K	Hold	65	–	–	﹤0.01%	513
2022 Q2	$5K	Hold	65	–	–	﹤0.01%	512
2022 Q1	$5K	Buy	+65	New	+$4.79K	﹤0.01%	521

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Hazlett, Burt & Watson's NVCR Position: Q1 2026 in Review

Hazlett, Burt & Watson held its NovoCure (NVCR) position steady in Q1 2026 at 65 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #891.

Hazlett, Burt & Watson first reported a position in NVCR in Q1 2022 and has held it in 17 quarters since. The position peaked at $5K in Q4 2022. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Hazlett, Burt & Watson held 65 shares of NovoCure worth $1K as of Q1 2026.
Hazlett, Burt & Watson left its NovoCure share count unchanged in Q1 2026.
NovoCure made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #891 holding.
Hazlett, Burt & Watson first reported a position in NovoCure in Q1 2022 and has held it in 17 quarters since.
Hazlett, Burt & Watson's NovoCure position peaked at $5K in Q4 2022.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.